Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$130.36 -1.1%	$122.78	$110.04 ▼ $238.00	$19.10B	0.12	1.41 million shs	1.24 million shs
CBPO China Biologic Products	$119.99	$119.23	$99.74 ▼ $120.05	$4.72B	0.47	148,695 shs	390,921 shs
EXEL Exelixis	$42.37 +0.4%	$38.90	$21.36 ▼ $48.85	$11.55B	0.28	2.32 million shs	2.10 million shs
NBIX Neurocrine Biosciences	$124.61 +0.1%	$110.03	$84.23 ▼ $157.98	$12.32B	0.24	1.13 million shs	742,957 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	-1.14%	-1.80%	+11.50%	-13.31%	-44.93%
CBPO China Biologic Products	0.00%	0.00%	0.00%	0.00%	0.00%
EXEL Exelixis	+0.36%	-0.54%	+14.95%	+9.82%	+92.94%
NBIX Neurocrine Biosciences	+0.07%	+0.77%	+4.78%	+10.24%	-6.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIIB Biogen	4.7099 of 5 stars	4.2	3.0	0.0	3.7	2.2	2.5	1.9
CBPO China Biologic Products	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	4.5013 of 5 stars	2.2	2.0	0.0	4.3	3.8	2.5	3.1
NBIX Neurocrine Biosciences	4.9739 of 5 stars	4.4	5.0	0.0	2.9	2.8	2.5	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIIB Biogen	2.38	Hold	$191.30	46.74% Upside
CBPO China Biologic Products	0.00	N/A	N/A	N/A
EXEL Exelixis	2.47	Hold	$39.35	-7.12% Downside
NBIX Neurocrine Biosciences	2.86	Moderate Buy	$162.00	30.01% Upside

Current Analyst Ratings Breakdown

Latest CBPO, BIIB, NBIX, and EXEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/5/2025	EXEL Exelixis	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$45.00 ➝ $46.00
6/2/2025	NBIX Neurocrine Biosciences	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$145.00
5/15/2025	EXEL Exelixis	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$45.00
5/15/2025	EXEL Exelixis	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $56.00
5/14/2025	EXEL Exelixis	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$40.00 ➝ $47.00
5/14/2025	EXEL Exelixis	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/14/2025	EXEL Exelixis	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$40.00 ➝ $40.00
5/14/2025	EXEL Exelixis	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$36.00 ➝ $38.00
5/7/2025	BIIB Biogen	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$207.00 ➝ $169.00
5/6/2025	NBIX Neurocrine Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/6/2025	NBIX Neurocrine Biosciences	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$137.00 ➝ $145.00

(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIIB Biogen	$9.82B	1.95	$21.41 per share	6.09	$114.71 per share	1.14
CBPO China Biologic Products	$503.70M	9.38	$5.01 per share	23.93	$45.09 per share	2.66
EXEL Exelixis	$2.30B	5.03	$2.33 per share	18.22	$8.02 per share	5.28
NBIX Neurocrine Biosciences	$2.41B	5.11	$3.63 per share	34.35	$25.97 per share	4.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIIB Biogen	$1.63B	$10.13	11.65	7.90	1.51	16.87%	14.98%	8.76%	7/30/2025 (Estimated)
CBPO China Biologic Products	$138.81M	$4.28	33.52	27.90	N/A	27.43%	8.32%	7.64%	N/A
EXEL Exelixis	$521.27M	$2.20	23.94	16.62	1.13	24.04%	23.52%	17.95%	8/5/2025 (Estimated)
NBIX Neurocrine Biosciences	$341.30M	$2.95	37.88	19.26	0.77	14.49%	13.38%	9.73%	7/30/2025 (Estimated)

Latest CBPO, BIIB, NBIX, and EXEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/5/2025	Q1 2025	NBIX Neurocrine Biosciences	$0.70	$0.08	-$0.62	$0.08	$587.06 million	$572.60 million
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
CBPO China Biologic Products	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIIB Biogen	0.27	1.35	0.90
CBPO China Biologic Products	N/A	12.01	10.13
EXEL Exelixis	N/A	3.63	3.58
NBIX Neurocrine Biosciences	N/A	3.40	3.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIIB Biogen	87.93%
CBPO China Biologic Products	34.77%
EXEL Exelixis	85.27%
NBIX Neurocrine Biosciences	92.59%

Insider Ownership

Company	Insider Ownership
BIIB Biogen	0.16%
CBPO China Biologic Products	2.73%
EXEL Exelixis	2.85%
NBIX Neurocrine Biosciences	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIIB Biogen	8,720	146.53 million	146.14 million	Optionable
CBPO China Biologic Products	2,269	39.36 million	N/A	Optionable
EXEL Exelixis	1,220	272.71 million	271.90 million	Optionable
NBIX Neurocrine Biosciences	1,200	98.97 million	95.42 million	Optionable

CBPO, BIIB, NBIX, and EXEL Headlines

Recent News About These Companies

Nxera Pharma earns $15m payment as first patient in schizophrenia drug trial is dosed by Neurocrine Biosciences

June 6 at 6:34 AM | cambridgeindependent.co.uk

Guggenheim Maintains Buy Rating on Neurocrine Biosciences Following Investor Meeting

June 6 at 6:34 AM | msn.com

Wealth Enhancement Advisory Services LLC Increases Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

June 6 at 3:56 AM | marketbeat.com

Rhumbline Advisers Has $34.78 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

June 5 at 4:42 AM | marketbeat.com

GAMMA Investing LLC Grows Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

June 5 at 4:31 AM | marketbeat.com

Neurocrine Biosciences (NASDAQ:NBIX) Earns Outperform Rating from Royal Bank of Canada

June 4 at 1:43 AM | americanbankingnews.com

CPRX or NBIX: Which Is the Better Value Stock Right Now?

June 3 at 12:40 PM | zacks.com

Nxera earns $15 million as Neurocrine advances schizophrenia drug

June 3 at 10:36 AM | thepharmaletter.com

Nxera wins $15m from Neurocrine Biosciences via schizophrenia drug dosing

June 3 at 5:34 AM | businessweekly.co.uk

Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568

June 2, 2025 | globenewswire.com

Neurocrine Biosciences' (NBIX) "Outperform" Rating Reiterated at Royal Bank of Canada

June 2, 2025 | marketbeat.com

Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia

June 2, 2025 | prnewswire.com

Summit Global Investments Sells 21,182 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

June 1, 2025 | marketbeat.com

Central Pacific Bank Trust Division Decreases Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

June 1, 2025 | marketbeat.com

First Hawaiian Bank Has $724,000 Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

June 1, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Purchases New Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

June 1, 2025 | marketbeat.com

Kevin Charles Gorman Sells 9,613 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

May 31, 2025 | marketbeat.com

California State Teachers Retirement System Boosts Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

May 31, 2025 | marketbeat.com

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Kevin Charles Gorman Sells 9,613 Shares

May 30, 2025 | insidertrades.com

Lansforsakringar Fondforvaltning AB publ Buys New Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

May 30, 2025 | marketbeat.com

Siemens Fonds Invest GmbH Buys Shares of 6,225 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

May 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBPO, BIIB, NBIX, and EXEL Company Descriptions

Biogen NASDAQ:BIIB

$130.36 -1.50 (-1.14%)

Closing price 06/5/2025 04:00 PM Eastern

Extended Trading

$130.42 +0.06 (+0.05%)

As of 09:01 AM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

China Biologic Products NASDAQ:CBPO

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.

Exelixis NASDAQ:EXEL

$42.37 +0.15 (+0.36%)

Closing price 06/5/2025 04:00 PM Eastern

Extended Trading

$42.38 +0.02 (+0.04%)

As of 09:02 AM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Neurocrine Biosciences NASDAQ:NBIX

$124.61 +0.09 (+0.07%)

Closing price 06/5/2025 04:00 PM Eastern

Extended Trading

$125.11 +0.50 (+0.40%)

As of 09:02 AM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time